Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: A pilot study

Onkologie

Volumn 28, Issue 12, 2005, Pages 647-650

  Laack, Eckart ^a   Andritzky, Birte ^a   Dürk, Heinz ^b   Burkholder, Iris ^c   Edler, Lutz ^c   Schuch, Gunter ^a   Boeters, Ina ^a   Görn, Michael ^a   Lipp, Rainer ^d   Horst, Hartmut ^d   Popp, Johann ^a   Hossfeld, Dieter K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b St Marien Hospital Hamm   (Germany)

^c Deutsches Krebsforschungsinstitut Heidelberg ^*  (Germany)

^d Onkologische Schwerpunktpraxis Lerchenfeld   (Germany)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Esophageal cancer; Pilot study

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; HISTAMINE H3 RECEPTOR ANTAGONIST;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LEUKOPENIA; LIVER METASTASIS; LOWER ESOPHAGUS SPHINCTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERFORMANCE; PILOT STUDY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; GERMANY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; TAXOIDS; TREATMENT OUTCOME;

EID: 28744439013     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089102     Document Type: Article

References (13)

1. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000 - cancer incidence, mortality and prevalence worldwide. Version 1.0. 2001
2. Vizcaino AP, Moreno V, Lambert R, et al.: Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.
3. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T: Randomized phase II study of cisplatin and 5-fluorouracil versus cisplatin alone in advanced squamous cell esophageal cancer. Eur J Cancer 1997;33:1216-1220.
4. Stahl M: Chemotherapy of esophageal carcinoma. Onkologie 1999;22:98-104.
5. Simon R: Design, analysis, and reporting of cancer clinical trials; in Karl E, Peace M (eds): Biopharmaceutical Statistics for Drug Development. New York, Dekker, 1998.
6. Schull B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F, Scheithauer W: Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology 2003;65:211-217.
7. Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM: A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 2002;32:115-123.
8. Einzig AL, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Steward JA, Benson AB 3rd: Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
9. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA: Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002;20:95-99.
10. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003;89:630-633.
11. Petrasch S, Welt A, Reinacher A, Graeven U, Koenig M, Schmiegel W: Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic esophageal cancer. Br J Cancer 1998;78:511-514.
12. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
13. Ajani J, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091.